Fulvestrant solution

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Sci Bull. 2025 Sep 29:S2095-9273(25)00984-3. [Abstract]

Customer Validation
MCF7 cells were incubated in stripping medium for 3 d and were pre-treated with Fulvestrant (10 µM, 0.5 h) followed by ChIP with anti-ESRRA specific antibody.

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 22;16(1):7854. [Abstract]

Customer Validation
The colony formation assay was used to measure LCC2 cell proliferation after treatment with Bufalin or Fulvestrant (0-200 nM).

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 22;16(1):7854. [Abstract]

Customer Validation
Fulvestrant (2.0 mg/kg). Representative IHC images for detecting Ki67 expression in the tumor specimens.

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2025 Dec 17;17(829):eadp5088. [Abstract]

Customer Validation
Combined Palbociclib- and Fulvestrant-resistant cells, M-S and T-S, and the corresponding resistant cells, MPF-R and TPF-R, were treated with different inhibitors of the PI3K/AKT/mTOR pathway including Alpelisib (HY-15244; Alp; 1 μM in M-S/MPF-R and 250 to 500 nM in T-S/TPF-R), Capivasertib (Cap; 250 to 500 nM in M-S/MPF-R and 100 nM in T-S/TPF-R), Sapanisertib (Sap; 10 nM in M-S/MPF-R and 5 nM in T-S/TPF-R), and Gedatolisib (HY-10681; Ged; 10 nM) in combination with Palbociclib (HY-50767; Palbo; 200 nM) and Fulvestrant (HY-13636; Fulv; 100 nM) (n = 3 independent biological replicates per group, performed in duplicates).

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2025 Dec 17;17(829):eadp5088. [Abstract]

Customer Validation
Combined Palbociclib- and Fulvestrant-resistant cells (wild type ER+ breast cancer cells), ZPF-R, and the corresponding sensitive cells, Z-S, were treated with different inhibitors of PI3K/AKT/mTOR including Alpelisib (HY-15244; 6 μM), Capivasertib (50 nM), Sapanisertib (5 nM), and Gedatolisib (HY-10681; 5 nM) in combination with Palbociclib (HY-50767; 150 nM) and Fulvestrant (HY-13636; 100 nM) (n = 3 independent biological replicates per group, performed in duplicates).

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2025 Dec 17;17(829):eadp5088. [Abstract]

Customer Validation
Triple combination with Gedatolisib (HY-10681), Palbociclib (HY-50767), and Fulvestrant (HY-13636) effectively inhibits growth of PIK3CA-mutant ER+ tumor xenografts resistant to combined palbociclib and fulvestrant. MPF-R cells (1 × 106) resistant to combined palbociclib and fulvestrant were injected into the mammary fat pads of NOG CIEA mice, and tumors were allowed to establish for 2 weeks to a size of ≈30 mm3. Mice were then treated with the combination of Fulvestrant (100 mg/kg, sc weekly), Palbociclib (25 mg/kg, oral gavage daily), and Capivasertib (100 mg/kg, oral gavage daily; n = 6) or Alpelisib (HY-15244; 25 mg/kg, oral gavage daily; n = 5). Tumor size was measured weekly. Average tumor growth curves measured weekly and Tumor volumes measured after excision.

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Apr;56(4):663-674. [Abstract]

Customer Validation
Protein expression of ER and MYC during 1 h Fulvestrant treatment (100 nM) in MCF7 cells.

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Mar 16;37(3):387-402.e7. [Abstract]

Customer Validation
MCF-7 cells were seeded in 10^-11 M E2 to which Fulvestrant (F), Dabrafenib (D), Trametinib (T) or Selumetinib (S) were subsequently added at 10^-9, 10^-6, 10^-7 or 10^-6 M, respectively. After 6 days, proteins were measured by immunoblotting, and phosphorylation levels (as defined by the levels of the phosphorylated form over total protein) relative to the vehicle-treated cells were set to 1.

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Mar 16;37(3):387-402.e7. [Abstract]

Customer Validation
Top: cells were grown for 6 days in the presence of 10^-11 M E2 and 10^-9 M Fulvestrant, to which increasing concentration of Selumetinib was added. Cell numbers relative to the vehicle control are plotted. Bottom: the cells were treated similarly except 10^-6 M Selumetinib was used, and apoptosis was measured 6 days post-treatment.

Fulvestrant solution purchased from MedChemExpress. Usage Cited in: J Mol Med (Berl). 2019 Apr;97(4):541-552. [Abstract]

Customer Validation
HK-2 cells treated with genistein (15 μM) and/or TGFβ (5 ng/ml) for 24 h are assayed with anti-acetylated and anti-total histone 3 antibodies by Western blot. In a separate assay, cell lysates treated with TGFβ and genistein in the presence or absence of Fulvestrant (Fulvest, 1 μM) under the same condition were also assayed. The quantifications are presented underneath the blots based on three independent experiments.